Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.

Conforti, Claudio; Giuffrida, Roberta; Dianzani, Caterina; Di Meo, Nicola; Zalaudek, Iris

Conforti, Claudio; Giuffrida, Roberta; Dianzani, Caterina; Di Meo, Nicola; Zalaudek, Iris.

Conforti C; Department of Dermatology and Venereology, Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Giuffrida R; Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Dianzani C; Department of Plastic, Reconstructive and Cosmetic Surgery, Dermatology Section, Campus Bio-Medico University Hospital, Rome, Italy.
Di Meo N; Department of Dermatology and Venereology, Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Zalaudek I; Department of Dermatology and Venereology, Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.

Dermatol Ther ; 33(4): e13490, 2020 07.

Article in English | MEDLINE | ID: covidwho-154934

Subject(s)

Coronavirus Infections; Pandemics; Pneumonia, Viral; Psoriasis; Betacoronavirus; Biological Therapy/adverse effects; COVID-19; Humans; Psoriasis/diagnosis; Psoriasis/drug therapy; Psoriasis/epidemiology; Risk Assessment; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Psoriasis / Coronavirus Infections / Pandemics Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2020 Document Type: Article Affiliation country: Dth.13490

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google